tiprankstipranks
Advertisement
Advertisement

CMPX Stock Latest News

Analyst Reiterates Buy on Compass Therapeutics Ahead of Key FDA Catalyst; $7 Price Target Maintained
RatingsAnalyst Reiterates Buy on Compass Therapeutics Ahead of Key FDA Catalyst; $7 Price Target Maintained
3d ago
CMPX
Compass Therapeutics price target raised to $7 from $4 at Leerink
PremiumThe Fly
Compass Therapeutics price target raised to $7 from $4 at Leerink
28d ago
CMPX
Compass Showcases Promising Tovecimig Data, Eyes Commercialization
PremiumCompany Announcements
Compass Showcases Promising Tovecimig Data, Eyes Commercialization
2M ago
8K
CMPX
Compass Therapeutics Adopts Second Amended and Restated Bylaws
PremiumCompany Announcements
Compass Therapeutics Adopts Second Amended and Restated Bylaws
2M ago
8K
CMPX
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
PremiumCompany Announcements
Compass Therapeutics Shareholders Back Directors, Pay, Auditor Oversight
3M ago
8K
CMPX
Compass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
PremiumRatingsCompass Therapeutics Maintained at Buy as Analyst Cites Promising CTX-8371 Data and Reaffirms $24 Price Target
4M ago
CMPX
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
Premium
Ratings
Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
4M ago
CMPX
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
Premium
The Fly
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
4M ago
CMPX
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Micron initiated, Rambus downgraded: Wall Street’s top analyst calls
4M ago
MU
TU
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
PremiumThe Fly
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
4M ago
CMPX
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
PremiumThe Fly
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
4M ago
CMPX
Compass Therapeutics price target lowered to $6 from $12 at Stifel
PremiumThe Fly
Compass Therapeutics price target lowered to $6 from $12 at Stifel
4M ago
CMPX
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
PremiumThe FlyCompass Therapeutics selloff ‘an over-reaction,’ says Jefferies
4M ago
CMPX
Leerink says Compass data supports path forward for tovecimig in 2L BTC
Premium
The Fly
Leerink says Compass data supports path forward for tovecimig in 2L BTC
4M ago
CMPX
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
Premium
The Fly
Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC
4M ago
VZ
WW
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
PremiumRatings
Analyst Maintains Buy on Tovecimig Developer, Sees PFS Strength Underappreciated and Keeps $24 Price Target Unchanged
4M ago
CMPX
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
PremiumThe Fly
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
4M ago
CMPX
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
PremiumRatings
Buy Rating Reiterated on Compass Therapeutics as Tovecimig Combo Shows Strong PFS Benefit but OS Signal Clouded by Crossover Effects
4M ago
CMPX
Morning Movers: Domino’s Pizza sinks following first quarter results
PremiumThe Fly
Morning Movers: Domino’s Pizza sinks following first quarter results
4M ago
VZ
CPB
Compass Therapeutics Reports Positive Phase 2/3 BTC Results
PremiumCompany AnnouncementsCompass Therapeutics Reports Positive Phase 2/3 BTC Results
4M ago
8K
CMPX
Compass Therapeutics reports additional COMPANION-002 study results
Premium
The Fly
Compass Therapeutics reports additional COMPANION-002 study results
4M ago
CMPX
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
Premium
Ratings
Compass Therapeutics (CMPX): Favorable Risk‑Reward Ahead of Pivotal Tovecimig Data in Biliary Tract Cancer
5M ago
CMPX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >